1. Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada;
2. Program in Molecular and Systems Pharmacology, Laney Graduate School, Emory University, Atlanta, GA;
3. Octapharma Biopharmaceuticals GmbH, Molecular Biochemistry, Berlin, Germany;
4. School of Biological Sciences, Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA; and
5. Aflac Cancer and Blood Disorders Center, Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA